• Type 2 DM
  • Cardiovascular event risk reduction in Type 2 DM patients with established cardiovascular disease:
    • Initial dose: SC 0.25mg once a week *4/52
    • Maintenance: SC 0.5mg once a week, then may increase to 1mg after at least 4 weeks, then to 2mg after another 4 weeks
    • Max: 2mg/week
  • Pre-filled syringe:
    • 0.25mg/0.5mL
    • 0.5mg/0.5mL
    • 1mg/0.5mL
  • Administered once weekly, on the same day each week
  • Injected subcutaneously into the abdomen, thigh or upper arm.
  • Rotate injection sites with each dose.
  • Taken without regards to meals

Glucagon-like peptide 1 (GLP-1) agonist

It works by activating glucagon-like-peptide-1 (GLP-1) receptor, increasing insulin secretion, decreasing glucagon secretion and delaying gastric emptying (incretin mimetic).

  • Nausea
  • Vomiting
  • Diarrhea
  • Abdominal pain
  • Constipation
  • Diabetic retinopathy
  • Eructation
  • Hypoglycemia
  • Dyspepsia
  • GERD
  • Flatulence
  • Gastritis
  • Increased amylase and lipase
  • Injection site reaction

Blackbox warning:

Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) due to risk of thyroid C-cell tumors.

  • Hypersensitivity to components
  • Type 1 DM
  • Multiple endocrine neoplasia syndrome type 2
  • Children under 18 years
  • Breastfeeding
  • End stage renal disease
  • NYHA class IV heart failure
  • Pregnancy
  • Insulin
  • Sulfonylureas

                          Drug Status

Availability Prescription only
Pregnancy Contraindicated
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Ozempic 0.25mg, 0.5mg Injection 1’s Novo Nordisk Phillips Therapeutics
Ozempic 1mg Injection 1’s Novo Nordisk Phillips Therapeutics